Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Hong Kong · Delayed Price · Currency is HKD

16.06

-0.03 (-0.19%)

Jun 18, 2026, 4:08 PM HKT

-37.63% (1Y)

Market Cap	7.21B -39.0%
Revenue (ttm)	2.73B -9.5%
Net Income	266.27M -43.3%
EPS	1.15 -42.9%
Shares Out	224.98M
PE Ratio	13.96
Forward PE	n/a
Dividend	1.16 (7.21%)
Ex-Dividend Date	Jun 4, 2026

Volume	398,080
Open	15.99
Previous Close	16.09
Day's Range	15.92 - 16.48
52-Week Range	15.94 - 31.28
Beta	0.44
Analysts	Strong Buy
Price Target	39.04 (+143.09%)
Earnings Date	Apr 24, 2026

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2007

Employees 2,110

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6826

Full Company Profile

Financial Performance

In 2025, HKG:6826's revenue was 2.45 billion, a decrease of -8.71% compared to the previous year's 2.68 billion. Earnings were 251.01 million, a decrease of -40.30%.

Financial numbers in CNY Financial Statements